Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.

Literature DB >> 26204273

(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.

Powell Perng¹, Charles Marcus¹, Rathan M Subramaniam^1,2,3,4.

Abstract

OBJECTIVE: Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of (18)F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma.
CONCLUSION: FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

Entities: Disease Gene Species

Keywords: FDG PET/CT; immune modulation therapy; melanoma

Mesh：

Substances：

Year: 2015 PMID： 26204273 DOI： 10.2214/AJR.14.13575

Source DB: PubMed Journal: AJR Am J Roentgenol ISSN： 0361-803X Impact factor: 3.959

Keyword Cloud
Cited

16 in total

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Authors: Narjess Ayati; Ramin Sadeghi; Zahra Kiamanesh; Sze Ting Lee; S Rasoul Zakavi; Andrew M Scott
Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-29 Impact factor: 9.236

Review 2. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

Authors: Minghao Wu; Yanyan Zhang; Yuwei Zhang; Ying Liu; Mingjie Wu; Zhaoxiang Ye
Journal: Radiol Imaging Cancer Date: 2019-11-29

3. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.

Authors: Emily B Ehlerding; Christopher G England; Rebecca L Majewski; Hector F Valdovinos; Dawei Jiang; Glenn Liu; Douglas G McNeel; Robert J Nickles; Weibo Cai
Journal: Mol Pharm Date: 2017-04-12 Impact factor: 4.939

4. Non-Cutaneous Melanoma, Findings and Prognostic Value of FDG PET/CT: A Case Series of 23 patients and review of the literature.

Authors: Bahare Saidi; Babak Fallahi; Armaghan Fard-Esfahani; Alireza Emami-Ardekani; Mohammad Eftekhari
Journal: Asia Ocean J Nucl Med Biol Date: 2022

5. Atypical spleen tuberculosis in a melanoma patient accidentally detected during a ¹⁸F-FDG PET/CT study: Case report.

Authors: Paulina Cegla; Arkadiusz Spychala; Andrzej Marszalek; Ewa Wierzchoslawska; Witold Cholewinski
Journal: Mol Clin Oncol Date: 2017-11-13

6. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?

Authors: Matteo Bauckneht; Roberta Piva; Gianmario Sambuceti; Francesco Grossi; Silvia Morbelli
Journal: World J Radiol Date: 2017-02-28

7. A Rare Case of Sinonasal Malignant Melanoma - Local, Regional, and Distant Spread Accurately Detected by 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors: Girish Kumar Parida; Sarthak Tripathy; Sreedharan Tripathy Arun; Madhavi Tripathi; Shamim Ahmed Shamim
Journal: Indian J Nucl Med Date: 2020-03-12

8. Evaluation of ¹⁸F-FDG PET/CT Parameters for Detection of Lymph Node Metastasis in Cutaneous Melanoma.

Authors: Jongtae Cha; Soyoung Kim; Jiyoung Wang; Mijin Yun; Arthur Cho
Journal: Nucl Med Mol Imaging Date: 2017-09-25

9. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.

Authors: Katy K Tsai; Miguel H Pampaloni; Charity Hope; Alain P Algazi; Britt-Marie Ljung; Laura Pincus; Adil I Daud
Journal: J Immunother Cancer Date: 2016-09-20 Impact factor: 13.751

10. ¹⁸F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.

Authors: Ralf S Eschbach; Philipp M Kazmierczak; Maurice M Heimer; Andrei Todica; Heidrun Hirner-Eppeneder; Moritz J Schneider; Georg Keinrath; Olga Solyanik; Jessica Olivier; Wolfgang G Kunz; Maximilian F Reiser; Peter Bartenstein; Jens Ricke; Clemens C Cyran
Journal: Cancer Imaging Date: 2018-01-18 Impact factor: 3.909

Review 1. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Review 2. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.